Guggenheim raised the firm’s price target on Elevance Health (ELV) to $399 from $396 and keeps a Buy rating on the shares. Q1 upside was “largely telegraphed, but nonetheless a favorable development as the company positions themselves for continued execution off its currently low earnings baseline,” the analyst tells investors post earnings.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $408 from $393 at Barclays
- Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
- Elevance Health price target raised to $364 from $357 at Leerink
- Elevance Health price target raised to $331 from $317 at Baird
- AI Models Turn More Positive on Elevance Health After Guidance Boost